Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR

Código QR

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR

Catherine M Kuecker, Eva M Vivian Pharmacy Practice Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA Purpose: The purpose of this review article is to provide guidance to health care providers regarding the use of dapagliflozin–metformin XR (extended release...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kuecker CM, Vivian EM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	type 2 diabetes fixed dose combination therapy dapagliflozin-metformin XR metformin SGLT2 inhibitor Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/827fb93c84134002b6a1b48ce781d110
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
por: Schwartz SS, et al.
Publicado: (2016)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu H, et al.
Publicado: (2017)

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
por: Moses R
Publicado: (2010)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos I, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes BC, et al.
Publicado: (2019)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
por: Olga Yuryevna Sukhareva, et al.
Publicado: (2016)

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
por: Kawarasaki S, et al.
Publicado: (2020)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
por: Jadwiga Nessler
Publicado: (2021)

Canagliflozin review – safety and efficacy profile in patients with T2DM
por: Jakher H, et al.
Publicado: (2019)

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
por: Osonoi T, et al.
Publicado: (2020)

Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus
por: Zhang Q, et al.
Publicado: (2020)

Adjunctive therapy for glucose control in patients with type 1 diabetes
por: Harris K, et al.
Publicado: (2018)

Incidence and Survival of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Cirrhosis Who Were Treated with and without Metformin
por: Tangjarusritaratorn T, et al.
Publicado: (2021)

Combination of Metformin and Exercise in Management of Metabolic Abnormalities Observed in Type 2 Diabetes Mellitus
por: Jevtovic F
Publicado: (2021)

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study
por: Hassoun AAK, et al.
Publicado: (2016)

Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women
por: Leng W, et al.
Publicado: (2021)

Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes
por: Schweighofer N, et al.
Publicado: (2020)

A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up
por: Paczkowska A, et al.
Publicado: (2021)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko Y, et al.
Publicado: (2018)

Dissolution Profile Evaluation of Eight Brands of Metformin Hydrochloride Tablets Available in Jimma, Southwest Ethiopia
por: Umeta B, et al.
Publicado: (2021)

Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
por: Xie J, et al.
Publicado: (2019)

Assessment of Serum Vitamin B12 and Folate Levels and Macrocytosis in Patients with Type 2 Diabetes Mellitus on Metformin Attending Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A Cross-Sectional Study
por: Wale Tesega W, et al.
Publicado: (2021)

Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus
por: Albai O, et al.
Publicado: (2020)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen T, et al.
Publicado: (2020)

Evaluation of the Effect of an Aqueous Extract of Azadirachta indica (Neem) Leaves and Twigs on Glycemic Control, Endothelial Dysfunction and Systemic Inflammation in Subjects with Type 2 Diabetes Mellitus – A Randomized, Double-Blind, Placebo-Controlled Clinical Study
por: Pingali U, et al.
Publicado: (2020)

Metformin and Malignant Tumors: Not Over the Hill
por: Leng W, et al.
Publicado: (2021)

Metformin Induces Ultrastructural Alterations in Hepatocytes of Spontaneously Hypertensive Rats
por: Gharbaran,Rajendra
Publicado: (2014)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Santos Cavaiola T, et al.
Publicado: (2018)

MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
por: Na Wang, et al.
Publicado: (2019)

Empagliflozin in type 1 diabetes
por: Mathieu C, et al.
Publicado: (2019)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh H, et al.
Publicado: (2017)

Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus
por: I Yu Demidova, et al.
Publicado: (2009)

Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
por: Scheerer MF, et al.
Publicado: (2016)

Metformin Pretreatment Ameliorates Diabetic Nephropathy Induced by a Combination of High Fat Diet and Streptozotocin in Rats
por: Dallak,Mohammad, et al.
Publicado: (2018)

Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia
por: Gebrie D, et al.
Publicado: (2021)

Self-Monitoring of Blood Glucose and Hypoglycemia Association During Fasting in Ramadan Among Patients with Diabetes
por: Mansouri D, et al.
Publicado: (2020)

DEVELOPMENT, COMPUTATIONAL STUDIES AND VALIDATION OF SPECTROPHOTOMETRIC METHOD OF METFORMIN HYDROCHLORIDE IN PHARMACEUTICAL FORMULATIONS
por: Judeh,Ahmed Abu, et al.
Publicado: (2020)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
por: Shen L, et al.
Publicado: (2021)

Usability of WebXR Visualizations in Urban Planning
por: Michał Rzeszewski, et al.
Publicado: (2021)

Metformin Protects Against Thioacetamide Induced Liver injury in Rats
por: Al-Hashem,Fahaid, et al.
Publicado: (2018)